Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD20 in Relapsed/Refractory CLL
NCT00093314Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Oct 2004
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ofatumumab in chronic lymphocytic leukemia (CLL) (3 cohorts), sponsored by GSK. Primary endpoint: Safety and Adverse Events. Planned start Oct 2004; status: withdrawn.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00093314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093314.